Evolution of our thinking and design of cancer therapeutics has gone through a tortuous path in the last eighty or so years, since the first patient was treated with a chemical agent. Introduction of nitrogen mustard in the treatment of cancer in 1940’s was based on a serendipitous finding and observation during the second world war.

The hallmark of neoplastic transformation is a significant increase in master regulator complex network entropy of cancer cell. This happens as a result of breakdown of the fine interplay of the second law of thermodynamics with the living cell. The methodologies that have been employed towards elucidation of spatial genomics and polyomics of tumor mass, could be applied towards the generation of spatial master

The history of cancer therapeutics since its birth some eighty years ago has gone through a tortuous path guided by understanding of the mechanism of carcinogenesis and notorious for many excitements and frustrations. The birth of nitrogen mustard in 1940’s through a serendipitous observation during the Second World War, was guided by the perception that a poison that kills normal cells, could also kill cancer cells. The excitement generated by shrinkage of tumor mass was soon followed by disappointment and frustration caused by tumor regrowth. 

The common denominator among all is ignoring the most fundamental pillar on which the forward move of tumor mass is based, namely tumor evolution along the thermodynamics arrow of time. Tumor evolution in certain ways is akin to evolution of life on this planet, which has acquired higher levels of sophistication and diversity. Neoplastic transformation and its evolutionary path could be divided into three main phases: initiation, promotion, and progression. Our future cancer therapeutics is expected to intercept with this evolutionary path. This necessitates a deep understanding of the dynamics of this path, and the necessary means including AI, and Nano–delivery to execute this task.

Pancreatic Cancer (PC) with dismal prognosis poses a significant challenge to healthcare systems worldwide. PC is the fourth leading cause of cancer-related mortality globally and is projected to surpass lung cancer as the second foremost cause by 2030. The poor prognosis associated with PC is primarily due to the low rate of early detection, rapid progression, and limited treatment options. Chemotherapy remains a cornerstone of treatment for PC in all stages of disease.